Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

OBJECTIVES: The current gold-standard for the first-line treatment in IIIb/IV stages of epithelial ovarian cancer (EOC) is the combination of carboplatin and paclitaxel plus bevacizumab in some countries. In the era of personalized medicine, there is still uncertainty on the impact of several molecu...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Staropoli, Nicoletta, Ciliberto, Domenico, Chiellino, Silvia, Caglioti, Francesca, Del Giudice, Teresa, Gualtieri, Simona, Salvino, Angela, Strangio, Alessandra, Botta, Cirino, Pignata, Sandro, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5347729/
https://ncbi.nlm.nih.gov/pubmed/27764790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12633
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы